PDCD1 and cutaneous squamous cell carcinoma: Other mAbs for cancer therapy have been approved, including anti-PD-1 (nivolumab, pembrolizumab, and cemiplimab) and anti-PD-L1 (atezolizumab, durvalumab, and avelumab), with anti-tumor activity in several types of cancer, such as melanoma, lung cancer, Hodgkin lymphoma, metastatic anal cancer, cutaneous squamous cell carcinoma, and breast cancer, among others (46, 49–53).